JP2021517129A5 - - Google Patents
Info
- Publication number
- JP2021517129A5 JP2021517129A5 JP2020546926A JP2020546926A JP2021517129A5 JP 2021517129 A5 JP2021517129 A5 JP 2021517129A5 JP 2020546926 A JP2020546926 A JP 2020546926A JP 2020546926 A JP2020546926 A JP 2020546926A JP 2021517129 A5 JP2021517129 A5 JP 2021517129A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- pharmaceutical composition
- composition according
- cancer
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639587P | 2018-03-07 | 2018-03-07 | |
| US62/639,587 | 2018-03-07 | ||
| US201962807912P | 2019-02-20 | 2019-02-20 | |
| US62/807,912 | 2019-02-20 | ||
| PCT/IB2019/051733 WO2019171253A1 (en) | 2018-03-07 | 2019-03-04 | Anti-pd-1 antibody compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517129A JP2021517129A (ja) | 2021-07-15 |
| JP2021517129A5 true JP2021517129A5 (enExample) | 2022-03-11 |
| JP7312188B2 JP7312188B2 (ja) | 2023-07-20 |
Family
ID=66041593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546926A Active JP7312188B2 (ja) | 2018-03-07 | 2019-03-04 | 抗ｐｄ－１抗体組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210002369A1 (enExample) |
| EP (1) | EP3761954A1 (enExample) |
| JP (1) | JP7312188B2 (enExample) |
| KR (1) | KR102594028B1 (enExample) |
| CN (1) | CN112105343B (enExample) |
| AU (1) | AU2019232625B2 (enExample) |
| BR (1) | BR112020017935A2 (enExample) |
| IL (1) | IL277095B2 (enExample) |
| MX (1) | MX2020009275A (enExample) |
| WO (1) | WO2019171253A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| AU2020385048A1 (en) * | 2019-11-13 | 2022-06-02 | Pfizer Inc. | Stable aqueous anti-TFPI antibody formulation |
| TW202138006A (zh) * | 2019-12-13 | 2021-10-16 | 韓商三星Ｂｉｏｅｐｉｓ股份有限公司 | 穩定之抗-pd1抗體醫藥調配物 |
| US20230355757A1 (en) | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
| WO2021152175A1 (en) * | 2020-01-31 | 2021-08-05 | Sanofi | Pulmonary delivery of antibodies |
| CA3181776A1 (en) | 2020-05-26 | 2021-12-02 | Boehringer Ingelheim International Gmbh | Anti-pd-1 antibodies |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
| CN114652824A (zh) * | 2020-12-23 | 2022-06-24 | 上海药明生物技术有限公司 | 抗egfr和pd-1双特异性抗体制剂与保存方法 |
| US20240287185A1 (en) | 2021-06-23 | 2024-08-29 | Formycon Ag | Formulations of anti-pd1 antibodies |
| CN117881419A (zh) * | 2021-07-01 | 2024-04-12 | 天津立博美华基因科技有限责任公司 | 药物组合及其用途 |
| CA3224640A1 (en) * | 2021-07-09 | 2023-01-12 | Krishnan SAMPATHKUMAR | Pharmaceutical compositions of a pd-1 antibody and use of the same |
| JP2024532462A (ja) * | 2021-09-03 | 2024-09-05 | ドクター レディズ ラボラトリーズ リミテッド | 免疫チェックポイント阻害剤の安定性を改善する方法 |
| CN118076380A (zh) * | 2021-09-03 | 2024-05-24 | 雷迪博士实验室有限公司 | 免疫检查点抑制剂的药物配制物 |
| MX2024009994A (es) * | 2022-03-07 | 2024-08-22 | Mabxience Res S L | Formulaciones estables para anticuerpos. |
| US20260207493A1 (en) * | 2022-12-21 | 2026-07-23 | Formycon Ag | Formulations of anti-pd1 antibodies |
| WO2024171082A1 (en) | 2023-02-16 | 2024-08-22 | Sun Pharmaceutical Industries Limited | Stable protein compositions of anti-pd1 antibody |
| TW202508641A (zh) * | 2023-08-16 | 2025-03-01 | 大陸商上海邁晉生物醫藥科技有限公司 | 一種包含免疫綴合物的醫藥組成物及其用途 |
| WO2025174319A1 (en) * | 2024-02-16 | 2025-08-21 | Xbrane Biopharma Ab | Stable antibody formulation for intravenous use comprising nivolumab, histidine, sucrose, polysorbate and methionine |
| SE548163C2 (en) * | 2024-02-16 | 2026-04-13 | Xbrane Biopharma Ab | Stable antibody formulation comprising nivolumab, histidine, sucrose, polysorbate and methionine |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| CA2602316A1 (en) * | 2005-03-23 | 2006-09-28 | Pfizer Products Inc. | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| MX2012012927A (es) * | 2010-05-06 | 2013-05-01 | Novartis Ag | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). |
| BR112013025845A2 (pt) * | 2011-04-07 | 2018-09-04 | Glaxosmithkline Llc | formulações com viscosidade reduzida |
| DK3049441T3 (da) * | 2013-09-27 | 2020-02-03 | Hoffmann La Roche | Anti-PDL1-antistofformuleringer |
| TWI731535B (zh) * | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| TW201617368A (zh) * | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2016120753A1 (en) * | 2015-01-28 | 2016-08-04 | Pfizer Inc. | Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation |
| EP3357508A4 (en) * | 2015-09-28 | 2019-04-24 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE |
| WO2017055966A1 (en) * | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| SG11201909941QA (en) * | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| US10646569B2 (en) * | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
-
2019
- 2019-03-03 IL IL277095A patent/IL277095B2/en unknown
- 2019-03-04 AU AU2019232625A patent/AU2019232625B2/en active Active
- 2019-03-04 WO PCT/IB2019/051733 patent/WO2019171253A1/en not_active Ceased
- 2019-03-04 EP EP19715555.9A patent/EP3761954A1/en active Pending
- 2019-03-04 MX MX2020009275A patent/MX2020009275A/es unknown
- 2019-03-04 US US16/978,354 patent/US20210002369A1/en active Pending
- 2019-03-04 BR BR112020017935-3A patent/BR112020017935A2/pt unknown
- 2019-03-04 CN CN201980030480.7A patent/CN112105343B/zh active Active
- 2019-03-04 KR KR1020207028149A patent/KR102594028B1/ko active Active
- 2019-03-04 JP JP2020546926A patent/JP7312188B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7842070B2 (ja) | 抗ｃｄ３８抗体の皮下製剤及びその使用 | |
| JP2024102215A5 (enExample) | ||
| JP2020518600A5 (enExample) | ||
| JP2021524256A5 (enExample) | ||
| JP7448552B2 (ja) | がんの併用療法 | |
| RS56210B1 (sr) | Formulacije sa visokom koncentracijom antitela | |
| BR112019022698A2 (pt) | formulações estáveis de anticorpos anti-tigit isolados e em combinação com anticorpos do receptor de morte programada 1 (pd-1) e métodos de uso das mesmas | |
| JP2018503365A5 (enExample) | ||
| CN107252485A (zh) | 用于诱导对疾病的免疫应答的组合疗法 | |
| JP2015500207A5 (enExample) | ||
| RU2017111228A (ru) | Композиции антитела против IL-7R | |
| US8992915B2 (en) | Combination of CD37 antibodies with ICE | |
| RU2017107559A (ru) | Лечение раковых заболеваний с применением анти-nkg2a средств | |
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| KR20250004789A (ko) | Pd-1 항체를 함유하는 안정한 고농도 아르기닌 제제 및 그의 사용 방법 | |
| CN119584995A (zh) | 组合疗法 | |
| RU2020129226A (ru) | Композиции анти-pd-1 антител | |
| EP4722240A1 (en) | Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers and compositions thereof | |
| WO2025244529A1 (en) | Dosing regimen of an egfr binding and/or complement activating antibody | |
| HK40126447A (en) | Subcutaneous formulations of anti-cd38 antibodies and their uses | |
| WO2025072516A1 (en) | Methods of reducing weight loss using anti-gdf15 antibodies | |
| CN115944741A (zh) | 含TGF-β受体的融合蛋白与紫杉类、核苷类似物联合在制备治疗胰腺癌药物中的用途 | |
| HK40041199B (en) | Anti-pd-1 antibody compositions | |
| EA053009B1 (ru) | Составы антител к cd38 для подкожного введения и их применение |